$0.34
1.44%
Downside
Day's Volatility :1.44%
Upside
0.0%
40.0%
Downside
52 Weeks Volatility :48.91%
Upside
14.85%
Period | Asensus Surgical Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 35.5% | 6.5% | 0.0% |
6 Months | 24.96% | 7.1% | 0.0% |
1 Year | -33.45% | 9.8% | 0.0% |
3 Years | -84.87% | 14.2% | -20.2% |
Market Capitalization | 92.4M |
Book Value | $0.05 |
Earnings Per Share (EPS) | -0.3 |
Wall Street Target Price | 0.35 |
Profit Margin | 0.0% |
Operating Margin TTM | -1616.56% |
Return On Assets TTM | -67.39% |
Return On Equity TTM | -169.75% |
Revenue TTM | 8.7M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 15.1% |
Gross Profit TTM | -3.8M |
EBITDA | -70.3M |
Diluted Eps TTM | -0.3 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.24 |
EPS Estimate Next Year | -0.19 |
EPS Estimate Current Quarter | -0.05 |
EPS Estimate Next Quarter | -0.05 |
What analysts predicted
Upside of 2.94%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 24.1M | ↑ 238.94% |
Net Income | -61.8M | ↓ 57.34% |
Net Profit Margin | -256.31% | ↑ 1779.92% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 8.5M | ↓ 64.6% |
Net Income | -154.2M | ↑ 149.61% |
Net Profit Margin | -1.8K% | ↓ 1551.23% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.2M | ↓ 62.78% |
Net Income | -59.3M | ↓ 61.54% |
Net Profit Margin | -1.9K% | ↓ 60.55% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 8.2M | ↑ 159.28% |
Net Income | -62.5M | ↑ 5.31% |
Net Profit Margin | -758.77% | ↑ 1109.32% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 7.1M | ↓ 13.91% |
Net Income | -75.6M | ↑ 20.97% |
Net Profit Margin | -1.1K% | ↓ 307.42% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 8.6M | ↑ 21.02% |
Net Income | -78.4M | ↑ 3.8% |
Net Profit Margin | -914.46% | ↑ 151.73% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.5M | ↓ 3.86% |
Net Income | -17.9M | ↓ 5.46% |
Net Profit Margin | -726.06% | ↑ 12.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 976.0K | ↓ 60.39% |
Net Income | -22.2M | ↑ 24.19% |
Net Profit Margin | -2.3K% | ↓ 1550.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1M | ↑ 10.76% |
Net Income | -20.7M | ↓ 7.0% |
Net Profit Margin | -1.9K% | ↑ 365.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1M | ↑ 0.74% |
Net Income | -18.3M | ↓ 11.34% |
Net Profit Margin | -1.7K% | ↑ 229.29% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.4M | ↑ 398.71% |
Net Income | -17.2M | ↓ 5.91% |
Net Profit Margin | -317.34% | ↑ 1364.75% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.1M | ↓ 79.32% |
Net Income | -22.5M | ↑ 30.53% |
Net Profit Margin | -2.0K% | ↓ 1685.95% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 239.3M | ↓ 4.37% |
Total Liabilities | 70.8M | ↓ 0.86% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 74.8M | ↓ 68.75% |
Total Liabilities | 19.2M | ↓ 72.81% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 78.3M | ↑ 4.65% |
Total Liabilities | 16.7M | ↓ 13.28% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 186.5M | ↑ 138.28% |
Total Liabilities | 17.2M | ↑ 3.22% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 116.1M | ↓ 37.76% |
Total Liabilities | 16.4M | ↓ 4.75% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 60.5M | ↓ 47.84% |
Total Liabilities | 27.1M | ↑ 65.29% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 116.1M | ↓ 9.79% |
Total Liabilities | 16.4M | ↑ 4.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 96.5M | ↓ 16.83% |
Total Liabilities | 16.8M | ↑ 2.43% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 78.4M | ↓ 18.81% |
Total Liabilities | 16.9M | ↑ 0.37% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 70.7M | ↓ 9.75% |
Total Liabilities | 23.5M | ↑ 39.16% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 60.5M | ↓ 14.41% |
Total Liabilities | 27.1M | ↑ 15.53% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 40.8M | ↓ 32.58% |
Total Liabilities | 27.8M | ↑ 2.47% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -48.5M | ↑ 21.86% |
Investing Cash Flow | -53.5M | ↓ 1070.79% |
Financing Cash Flow | 26.5M | ↓ 74.66% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -73.5M | ↑ 51.54% |
Investing Cash Flow | 67.6M | ↓ 226.48% |
Financing Cash Flow | -5.6M | ↓ 121.2% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -46.7M | ↓ 36.48% |
Investing Cash Flow | -3.0K | ↓ 100.0% |
Financing Cash Flow | 53.4M | ↓ 1051.51% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -40.7M | ↓ 12.89% |
Investing Cash Flow | -119.7M | ↑ 3988833.33% |
Financing Cash Flow | 161.7M | ↑ 202.99% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -58.9M | ↑ 44.95% |
Investing Cash Flow | 47.5M | ↓ 139.72% |
Financing Cash Flow | -332.0K | ↓ 100.21% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.1M | ↓ 4.1% |
Investing Cash Flow | 6.3M | ↓ 64.92% |
Financing Cash Flow | 194.0K | ↓ 19500.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.2M | ↑ 22.74% |
Investing Cash Flow | 29.7M | ↑ 370.0% |
Financing Cash Flow | -483.0K | ↓ 348.97% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.0M | ↑ 4.1% |
Investing Cash Flow | 6.6M | ↓ 77.93% |
Financing Cash Flow | 194.0K | ↓ 140.17% |
Sell
Neutral
Buy
Asensus Surgical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Asensus Surgical Inc | 1.57% | 24.96% | -33.45% | -84.87% | -91.73% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Asensus Surgical Inc | NA | NA | NA | -0.24 | -1.7 | -0.67 | NA | 0.05 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Asensus Surgical Inc | Hold | $92.4M | -91.73% | NA | 0.0% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Asensus Surgical Inc
Revenue is down for the last 2 quarters, 5.43M → 1.12M (in $), with an average decrease of 79.3% per quarter
Netprofit is down for the last 2 quarters, -17.23M → -22.49M (in $), with an average decrease of 30.5% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 75.2%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 153.8%
asensus aps is a computer software company based out of 22a vallensbækvej, brondby, capital region of denmark, denmark.
Organization | Asensus Surgical Inc |
Employees | 207 |
CEO | Mr. Anthony Fernando |
Industry | Healthcare |